Preclinical Safety Assessment: Current Gaps, Challenges, and Approaches in Identifying Translatable Biomarkers of Drug-Induced Liver Injury

Clinics in Laboratory Medicine

Volumn 31, Issue 1, 2011, Pages 161-172

  Ramaiah, Shashi K ^a  

^a PFIZER INC   (United States)

Author keywords

Biomarkers; Laboratory animal; Liver; Preclinical; Translatable

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGINASE 1; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE ALPHA; ISOENZYME; MALATE DEHYDROGENASE; MICRORNA; NUCLEIC ACID; PURINE NUCLEOSIDE PHOSPHORYLASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DRUG-INDUCED LIVER INJURY; ISOENZYMES; MODELS, ANIMAL; RNA, MESSENGER; TOXICITY TESTS;

EID: 79551484754     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.10.004     Document Type: Review

References (35)

1. Abboud G., Kaplowitz N. Drug-induced liver injury. Drug Saf 2007, 30(4):277-294.
2. Zimmerman H.J. Drug-induced liver disease. Schiff's diseases of the liver 1999, 973-1064. Lippincott-Raven, Baltimore (MD). E. Schiff (Ed.).
3. Senior J.R. Monitoring for hepatotoxicity: what is the predictive value of liver " function" tests?. Clin Pharmacol Ther 2009, 85:331-334.
4. Watkins P.B. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis 2009, 29:393-399.
5. Shenton J.M., Chen J., Uetrecht J.P. Animal models of idiosyncratic drug reactions. Chem Biol Interact 2004, 150(1):53-70.
6. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009, 29:383-392.
7. Uetrecht J. Idiosyncratic drug reactions: past, present and future. Chem Res Toxicol 2008, 21:84-92.
8. Adams D.H., Ju C., Ramaiah S.K., et al. Mechanisms of immune mediated liver injury. Toxicol Sci 2010, 115:307-321.
9. Boelsterli U.A., Hsiao C.J. The heterozygous Sod2(+/-) mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 2008, 13(21-22):982-988.
10. Deng X., Stachlewitz R.F., Liguori M.J., et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006, 319(3):1191-1199.
11. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the " danger hypothesis" and innate immune system. Chem Res Toxicol 1999, 12(5):387-395.
12. Ozer J., Ratner M., Shaw M., et al. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245(3):194-205.
13. Ozer J., Chetty R., Kenna G., et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 2009, 56:237-246.
14. Ozer J., Chetty R., Kenna G., et al. Gaps for qualifying biomarker candidates of drug induced liver injury. Biomark Med 2010, 4:475-483.
15. Amacher D.E. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998, 27(2):119-130.
16. Ramaiah S.K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem Toxicol 2007, 45(9):1551-1557.
17. Ozer J.S., Reagan W.J., Schomaker S., et al. Translational biomarkers of acute drug-induced liver injury: the current state, gaps and future opportunities. Biomarkers of medicine, drug discovery and environmental health 2010, 203-227. John Wiley & Sons, Inc. 1st edition. V.S. Vaidya, J.V. Bonventre (Eds.).
18. Goodsaid F.M., Frueh F.W., Mattes W. Strategic paths for biomarker qualification. Toxicology 2008, 245:219-223.
19. Amacher D.E., Adler R., Herath A., et al. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005, 51(10):1796-1803.
20. Ferre N., Camps J., Prats E., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002, 48(2):261-268.
21. Kawai M., Hosaki S. Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease. Clin Biochem 1990, 23(4):327-334.
22. Lindblom P., Rafter I., Copley C., et al. Isoforms of alanine aminotransferases in human tissues and serum-differential tissue expression using novel antibodies. Arch Biochem Biophys 2007, 466(1):66-77.
23. Yang R.Z., Park S., Reagan W.J., et al. Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity. Hepatology 2009, 49(2):598-607.
24. Reagan WJ, Park S, Goldstein R, et al. Hepatic ALT1 and 2 proteins are differentially regulated by dexamethazone treatment in mice. Society of Toxicology Meeting Abstract 2008.
25. Liu L., Zhong S., Yang R., et al. Expression, purification, and initial characterization of human alanine aminotransferase (ALT) isoenzyme 1 and 2 in high-five insect cells. Protein Expr Purif 2008, 60(2):225-231.
26. Bala S., Marcos M., Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol 2010, 15:5633-5640.
27. Wang K., Zhang S., Marzolf B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009, 106:4402-4407.
28. Wetmore B.A., Brees D.J., Singh R., et al. Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology 2010, 51:2127-2139.
29. Murayama H., Ikemoto M., Fukuda Y., et al. Advantage of serum type-I arginase and ornithine carbamoyltransferase in the evaluation of acute and chronic liver damage induced by thioacetamide in rats. Clin Chim Acta 2007, 375:63-68.
30. Ikemoto M., Tsunekawa S., Tanaka K., et al. Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance. Clin Chim Acta 1998, 271:11-23.
31. Giffen P.S., Pick C.R., Price M.A., et al. Alpha-glutathione- S-transferase in the assessment of hepatotoxicity-its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 2002, 30:365-372.
32. Beckett G.J., Foster G.R., Hussey A.J., et al. Plasma glutathione- S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem 1989, 35(11):2186-2189.
33. Banerjee A., Burghardt R.C., Johnson G.A., et al. The temporal expression of osteopontin (SPP-1) in the rodent model of alcoholic steatohepatitis: a potential biomarker. Toxicol Pathol 2006, 34(4):373-384.
34. Miller T.J., Knapton A., Adeyemo O., et al. Cytochrome c: a non invasive biomarker of drug-induced liver injury. J Appl Toxicol 2008, 28:815-828.
35. Dieterle F., Sistare F., Goodsaid F., et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010, 28:455-462.